These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Skin Diseases (Dermatitis / Psoriasis / Acne)
DBQ Overview
Interview + Physical- Form Name
- Skin_Diseases
- Form Code
- Skin_Diseases
- Page Count
- 12
- Examiner Type
- Dermatologist or appropriate clinician
- Estimated Duration
- 15-30 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To document the nature, severity, and extent of your skin condition for VA disability rating purposes under 38 CFR - 4.118. The examiner will determine the diagnosis, the total body surface area (TBSA) and exposed body surface area (EBSA) affected, treatment history, frequency of flare-ups, and functional impact on daily life and work.
What the examiner evaluates:
- Specific skin diagnosis (e.g., papulosquamous disorder, dermatitis, psoriasis, acne, eczema)
- Total body surface area (TBSA) affected - expressed as a percentage
- Exposed body surface area (EBSA) affected - expressed as a percentage
- Whether condition is active or in remission at time of exam
- Frequency, duration, and severity of flare-ups
- Involvement of special body areas: palmar, plantar, mucosal, intertriginous zones, face and neck
- Current and historical treatments including corticosteroids, biologics, retinoids, antihistamines, phototherapy, immunosuppressives
- Treatment-line history (first-line, second-line, third-line)
- Impact on daily activities, employment, and quality of life
- Presence of erythroderma or exfoliative dermatitis
- Scarring, alopecia, hyperhidrosis, or vitiligo as related complications
- Whether any complications warrant separate diagnostic codes (e.g., psoriatic arthritis)
The examiner will visually inspect affected skin areas and conduct a clinical interview. You may be asked to undress partially to allow full assessment. Bring all medications and a written symptom history. The exam often occurs at a VA medical center, CBOC, or contractor facility (e.g., VES, LHI, QTC). You have the right to request the exam be recorded in most states - check your state's one-party or two-party consent law beforehand.
Typical duration: 15-30 minutes
Total Body Surface Area (TBSA) Affected
The percentage of your entire body surface covered by the skin condition. This is a primary driver of your VA disability rating under the General Rating Formula for the Skin.
What to expect:
The examiner will visually estimate the percentage of your skin affected using the Rule of Nines or similar clinical estimation. They may measure or estimate areas on your trunk, extremities, scalp, face, and neck. This measurement must appear in the DBQ for the exam to be sufficient for rating purposes.
Key thresholds:
- Less than 5% TBSA — May support 0% if well-controlled or 10% with constant symptoms
- 5-20% TBSA or 20-40% EBSA — Supports 30% rating under General Formula
- More than 20% TBSA, or more than 40% EBSA, or systemic therapy required — Supports 60% rating under General Formula
Tips:
- Do not apply medications, cover up lesions, or use heavy cosmetics before the exam - the examiner must see your condition at its representative state.
- If your condition fluctuates, inform the examiner about your worst presentation even if the exam day is a better day.
- Ask the examiner to document both TBSA and EBSA explicitly - both are required for a sufficient rating exam per M21-1.
- Bring photographs taken during flare-ups to show the examiner the full extent of disease when active.
Pain considerations: Pain, burning, and pruritus associated with active lesions should be verbally reported to the examiner. Skin pain is not a separate DeLuca-type musculoskeletal factor but must be documented because it drives functional impairment used in the occupational and social impact section of the DBQ.
Exposed Body Surface Area (EBSA) Affected
The percentage of exposed (visible) body surface areas - such as the face, neck, and hands - that are affected. Involvement of exposed areas carries additional rating weight because of the social and occupational impact of visible lesions.
What to expect:
The examiner will separately assess what percentage of normally exposed skin is involved. Exposure of areas like face, neck, forearms, and hands may trigger higher rating criteria even if TBSA is lower.
Key thresholds:
- 20-40% of exposed areas — Supports 30% rating
- More than 40% of exposed areas — Supports 60% rating
Tips:
- Clearly identify to the examiner which areas are regularly exposed in your daily life and occupation.
- Face and neck involvement at 40% or more is explicitly noted on the DBQ and raises rating consideration.
- If you work outdoors or in a public-facing role, the functional impact of exposed-area involvement is amplified - communicate this.
Pain considerations: Lesions on exposed areas, particularly the face and hands, often cause social anxiety, avoidance behavior, and occupational limitations. Describe these impacts explicitly.
Special Area Involvement Assessment
Whether the condition affects functionally and clinically significant body areas including palms (palmar), soles (plantar), mucous membranes (mucosal), and skin folds (intertriginous areas such as axilla, groin, and anogenital region).
What to expect:
The examiner will check specific body sites. Palmar and plantar involvement are noted on DBQ checkboxes with episode frequency. Mucosal and intertriginous involvement are also separately recorded. These findings can affect rating level and may support analogous rating under higher criteria.
Key thresholds:
- Palmar or plantar involvement present — Can support 60% rating or higher analogous codes depending on frequency and severity
- Mucosal involvement present — Relevant to erythema multiforme, bullous disorders, and may trigger separate rating considerations
- Intertriginous involvement present — Noted in DBQ and supports higher severity documentation
Tips:
- Report all areas affected, including areas you might consider minor, such as inside your mouth, palms, or between skin folds.
- For palmar/plantar involvement, describe how many episodes per year you experience and how long each lasts.
- Intertriginous involvement (skin folds) is often underreported - describe any rashes, maceration, or secondary infections in these areas.
Pain considerations: Palmar and plantar psoriasis or eczema can be severely disabling due to cracking, bleeding, and pain with weight-bearing or manual tasks. Describe functional limitations such as inability to grip, walk, or perform daily tasks during flare-ups.
Flare-Up Frequency and Duration Assessment
How often your skin condition flares, how long flares last, what triggers them, and what the condition looks like during a flare versus remission.
What to expect:
The examiner will ask about frequency of active episodes, duration of remissions, and what treatments are required during flares. The DBQ captures whether the condition is currently active or in remission, and this is a critical rating driver.
Key thresholds:
- Constant or near-constant symptoms requiring ongoing systemic treatment — Supports 60% rating
- Frequent flares with intermittent remission — Supports 30% rating depending on area affected
- Infrequent flares, well-controlled with topical treatment only — May support 10% or 0% rating
Tips:
- Keep a symptom diary for the 60 days before your exam noting flare dates, severity, duration, and triggers.
- Do not describe only your average day - describe your worst days per M21-1 guidance.
- If the exam falls during a remission, explicitly tell the examiner: 'Today is a relatively controlled day; my condition is typically much worse.'
- Describe all known triggers: stress, temperature changes, dietary factors, occupational exposures, soaps/chemicals.
Pain considerations: During flares, describe all associated symptoms: pain, burning, pruritus, weeping lesions, bleeding cracks, and any systemic symptoms such as fatigue or joint pain (especially relevant for psoriasis).
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 60% | Characteristic lesions involving more than 20% of the entire body surface OR more than 40% of exposed body surface areas, OR requiring systemic therapy (oral or injectable steroids, biologics, immunosuppressives, retinoids) for a total duration of 6 weeks or more during the past 12-month period. |
CFR: General Rating Formula for the Skin at 60%: At least one of the following: characteristic lesions involving more than 20% of the entire body or more than 40% of exposed areas, OR systemic therapy such as corticosteroids or other immunosuppressives required for a total duration of six weeks or more over the past 12-month period. |
| 30% | Characteristic lesions involving 5-20% of the entire body surface OR 20-40% of exposed body surface areas, OR requiring intermittent systemic therapy (oral steroids, immunosuppressives, retinoids, biologics) for a total duration of less than 6 weeks during the past 12-month period. |
CFR: General Rating Formula for the Skin at 30%: At least one of the following: characteristic lesions involving 5% to 20% of entire body or 20% to 40% of exposed areas, OR systemic therapy such as corticosteroids or other immunosuppressives required for a total duration of less than six weeks over the past 12-month period. |
| 10% | At least one characteristic lesion present, OR condition requires topical therapy only (creams, ointments), with less than 5% of total body surface area affected. Condition is controlled but not absent. |
CFR: General Rating Formula for the Skin: at least one of the following: characteristic lesions involving less than 5% of entire body, or less than 5% of exposed areas, and; no more than topical therapy required during the past 12-month period. |
| 0% | No characteristic lesions, or only residual skin damage with no active disease, no treatment required, and no functional impairment. Condition is in complete, sustained remission. |
CFR: Under the General Rating Formula for the Skin (38 CFR - 4.118), 0% is assigned when the condition requires no treatment and produces no disability. |
60% Characteristic lesions involving more than 20% of the entire ...
Characteristic lesions involving more than 20% of the entire body surface OR more than 40% of exposed body surface areas, OR requiring systemic therapy (oral or injectable steroids, biologics, immunosuppressives, retinoids) for a total duration of 6 weeks or more during the past 12-month period.
Key Symptoms
- More than 20% TBSA affected
- More than 40% of exposed body surface affected
- Systemic therapy required 6 or more weeks per year
- Biologic medications in use
- Significant functional impairment, occupational limitations
- Frequent or prolonged flare-ups
- Palmar or plantar involvement with functional limitation
- Intertriginous, mucosal, or facial involvement
CFR: General Rating Formula for the Skin at 60%: At least one of the following: characteristic lesions involving more than 20% of the entire body or more than 40% of exposed areas, OR systemic therapy such as corticosteroids or other immunosuppressives required for a total duration of six weeks or more over the past 12-month period.
30% Characteristic lesions involving 5-20% of the entire body su ...
Characteristic lesions involving 5-20% of the entire body surface OR 20-40% of exposed body surface areas, OR requiring intermittent systemic therapy (oral steroids, immunosuppressives, retinoids, biologics) for a total duration of less than 6 weeks during the past 12-month period.
Key Symptoms
- 5-20% TBSA affected
- 20-40% of exposed body surface affected
- Intermittent use of systemic medications
- Requires oral steroids or second-line agents less than 6 weeks per year
- Moderate flare-up frequency with partial remission between episodes
CFR: General Rating Formula for the Skin at 30%: At least one of the following: characteristic lesions involving 5% to 20% of entire body or 20% to 40% of exposed areas, OR systemic therapy such as corticosteroids or other immunosuppressives required for a total duration of less than six weeks over the past 12-month period.
10% At least one characteristic lesion present, OR condition req ...
At least one characteristic lesion present, OR condition requires topical therapy only (creams, ointments), with less than 5% of total body surface area affected. Condition is controlled but not absent.
Key Symptoms
- Active lesions present but limited in extent
- Controlled with topical medications only
- Less than 5% TBSA affected
- Minimal functional impairment
CFR: General Rating Formula for the Skin: at least one of the following: characteristic lesions involving less than 5% of entire body, or less than 5% of exposed areas, and; no more than topical therapy required during the past 12-month period.
0% No characteristic lesions, or only residual skin damage with ...
No characteristic lesions, or only residual skin damage with no active disease, no treatment required, and no functional impairment. Condition is in complete, sustained remission.
Key Symptoms
- Complete remission with no active lesions
- No ongoing treatment required
- No functional limitations from skin condition
CFR: Under the General Rating Formula for the Skin (38 CFR - 4.118), 0% is assigned when the condition requires no treatment and produces no disability.
How to Describe Your Symptoms
Extent and Location of Active Lesions
How to describe:
Describe which body areas are currently affected and estimate what percentage of your body is covered. Use reference points: 'Both arms from wrist to elbow are fully involved, both lower legs are covered, and patches on my back and abdomen together cover roughly 25-30% of my body.' Specify face, neck, hands, and other exposed areas separately.
Worst-day example:
“On my worst days, the plaques cover both legs entirely from knee to ankle, spread across my lower back and abdomen, and I have patches on both arms. My palms crack and bleed, and I cannot make a full fist. I estimate 25-30% of my body is affected during a full flare, including visible areas on my face and forearms that I cannot hide at work.”
What the examiner listens for:
Specific body locations, percentage estimates, involvement of exposed versus non-exposed areas, and whether special sites (palms, soles, face, mucous membranes) are affected.
Understatements to avoid:
Do not say 'a few spots here and there' if your condition covers large areas during flares. Do not minimize involvement of the face or hands. Do not fail to mention mucosal or genital involvement if present.
Treatment Intensity and Duration
How to describe:
List every medication you use or have used, whether topical or systemic, and for how long you used it in the past 12 months. Include: corticosteroid creams, biologic injections (e.g., Humira, Skyrizi, Dupixent), oral retinoids, methotrexate, cyclosporine, antihistamines, and any phototherapy. State total weeks of use per year for systemic treatments.
Worst-day example:
“I have been on a biologic injection every two weeks for the past 14 months because topical steroids and oral methotrexate were no longer adequate. I also use high-potency topical steroids daily on resistant patches. I have been on systemic therapy continuously for more than 6 weeks in the past 12 months.”
What the examiner listens for:
Escalation of treatment over time, use of systemic or biologic agents, total duration of systemic therapy in the past year (the 6-week threshold is the key dividing line for 30% vs. 60% rating), and whether treatment has failed.
Understatements to avoid:
Do not omit any medication - even over-the-counter antihistamines or prescription topical calcineurin inhibitors. Do not understate total weeks of systemic treatment. Bring a medication list with start/stop dates.
Flare-Up Frequency, Triggers, and Severity
How to describe:
Describe how many times per year you have significant flares, how long they last, what triggers them, and what the skin looks like during a flare (plaques, scaling, oozing, cracking, pustules, erythema). Also describe periods of remission and how complete the remission is.
Worst-day example:
“I flare severely 4-6 times per year, with each flare lasting 3-6 weeks before partial control is achieved. During a flare, my skin is bright red, thickly scaled, extremely itchy, and bleeds if I scratch. I have never achieved complete clearance - even in remission I have at least 5-10% of my body still showing plaques.”
What the examiner listens for:
Frequency and duration of flares, whether remission is complete or partial, what the skin looks like at its worst, and whether there are any systemic symptoms during flares such as joint pain, fatigue, or fever.
Understatements to avoid:
Do not describe only your current state if today is a good day. Explicitly state: 'Today is better than average - my typical presentation is more severe.' Do not omit triggers such as stress, infection, or occupational exposures.
Functional and Occupational Impact
How to describe:
Describe how your skin condition limits your ability to work, perform daily tasks, socialize, exercise, or sleep. Mention any missed work days, limitations on lifting or gripping due to hand involvement, inability to wear certain clothing or equipment, or psychological effects such as social avoidance or depression.
Worst-day example:
“During flares, I cannot wear my work uniform because it irritates the plaques. I have missed an average of 2-3 days of work per month. My hand involvement prevents me from using tools or shaking hands. I avoid social situations because of the appearance of my skin on my face and arms, and I have been diagnosed with depression linked to my skin condition.”
What the examiner listens for:
Specific occupational limitations, missed work, impact on activities of daily living, psychological effects, and any assistive measures or accommodations required because of the skin condition.
Understatements to avoid:
Do not say 'it bothers me a little' if your condition significantly affects your work or social life. Be specific about missed days, tasks you cannot perform, and how the condition has changed your life over time.
Associated Symptoms and Complications
How to describe:
For psoriasis specifically, mention any joint pain (psoriatic arthritis), nail changes (pitting, onycholysis), scalp involvement, or eye conditions. For eczema/dermatitis, mention secondary bacterial infections, lichenification (thickening of skin), sleep disruption from itching, and any history of infections requiring antibiotics. These complications may warrant separate diagnostic codes and additional ratings.
Worst-day example:
“In addition to the skin plaques, I have joint pain and stiffness in both wrists and my lower back that my rheumatologist has diagnosed as psoriatic arthritis. My nails are pitted and one has separated from the nail bed. I have had three separate bacterial skin infections in the past 18 months requiring oral antibiotics.”
What the examiner listens for:
Evidence of systemic involvement, psoriatic arthritis, secondary infections, nail or scalp involvement, and any conditions that could be separately rated under other diagnostic codes per the note in DC 7816.
Understatements to avoid:
Do not omit joint pain, nail changes, or eye symptoms when claiming psoriasis. Do not fail to mention secondary infections - these may support a separate claim under DC 7820 or an increased rating.
Common Mistakes to Avoid
Applying heavy moisturizer, covering lesions with makeup, or treating skin aggressively immediately before the exam
This artificially minimizes the visible extent of your condition and can cause the examiner to underestimate TBSA and EBSA, directly lowering your rating.
Instead: Allow your skin to present in its representative state. You may use your normal medications but avoid cosmetic coverup of lesions on the day of the exam. Bring photographs showing your skin during typical or worst-day presentations.
Impact: All levels, particularly the difference between 10% and 30%
Describing only the current day's condition without mentioning your worst-day presentation
VA ratings under M21-1 guidance consider the condition as it exists across its full range of severity. If the exam falls on a good day, the examiner may document only the mild presentation they observe.
Instead: Proactively tell the examiner: 'Today is one of my better days. During a typical flare my skin looks like [description], affecting approximately [X]% of my body.' Provide photographs taken during flares.
Impact: 30% vs. 60% - the TBSA threshold is the primary determiner
Failing to bring a complete, accurate medication list with duration of use
The DBQ specifically records which medications were used and for how long. The critical rating threshold between 30% and 60% depends on whether systemic therapy was used for more or fewer than 6 weeks in the past 12 months. If you cannot document this, the examiner may record it as less than 6 weeks.
Instead: Bring a written medication log with drug names, doses, start and stop dates, and the reason each was prescribed. Obtain pharmacy printouts if possible. Calculate total weeks of systemic treatment use in the past year before the exam.
Impact: 30% vs. 60%
Not mentioning palmar, plantar, mucosal, or intertriginous involvement
These special body areas are explicitly captured on the DBQ and can support higher rating levels or analogous codes. Veterans often omit involvement of palms, soles, genitals, or mouth because they consider these embarrassing or minor.
Instead: Disclose all affected areas completely, including sensitive areas. These findings directly influence the examiner's documentation and rating recommendation.
Impact: 30% vs. 60%, and may unlock separate rating codes
Failing to report complications such as psoriatic arthritis, nail changes, or secondary infections
Under DC 7816, complications such as psoriatic arthritis are rated separately under the appropriate diagnostic code. If you do not report joint pain, nail changes, or recurrent infections, these conditions will not be documented for separate rating consideration.
Instead: Report all related conditions including joint pain, stiffness, nail pitting, eye inflammation, and any infections. Ask whether a separate DBQ for arthritis or other complications should be completed.
Impact: Affects total combined disability rating through additional separate claims
Not mentioning psychological or occupational impact
The DBQ has a specific functional impact section. If you do not describe how the condition affects your work, social life, and daily activities, the examiner may leave this section blank or minimize it, reducing documentation supporting TDIU or secondary psychiatric claims.
Instead: Describe specific functional limitations: missed work days, inability to perform job duties, social avoidance, sleep disruption from itching, depression or anxiety diagnosis, and any workplace accommodations required.
Impact: Supports TDIU, secondary psychiatric claims, and highest rating levels
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to a thorough, in-person examination unless a records-only review is appropriate - if your skin condition requires visual inspection for accurate assessment, you may request an in-person exam.
- You have the right to record your C&P examination in most states - check your state's recording consent laws before the exam.
- You have the right to submit a written rebuttal or request a supplemental exam if the C&P report contains factual inaccuracies or is insufficient for rating purposes under M21-1.
- Per M21-1, a skin examination report that fails to identify both total body surface area (TBSA) and exposed body surface area (EBSA) as percentages is considered insufficient for rating purposes - you may request a new exam if these are missing.
- You have the right to submit buddy statements, personal statements, and photographic evidence in support of your claim - these are part of the evidence of record.
- You have the right to have your condition rated based on your worst-day presentation, not solely the condition observed on exam day, per M21-1 guidance.
- You have the right to representation by an accredited VSO, attorney, or claims agent at no cost to you for initial claims.
- You have the right to appeal a rating decision through the Supplemental Claim, Higher-Level Review, or Board of Veterans' Appeals lanes under the AMA framework.
- If the examiner fails to examine you in person and conducts only a records review, you have the right to a statement explaining how the exam was conducted - this is documented on the DBQ.
- Psoriasis complications (such as psoriatic arthritis) must be rated separately under appropriate diagnostic codes per the note in 38 CFR - 4.118, DC 7816 - you have the right to separate ratings for each ratable complication.
Related Conditions
- Psoriatic Arthritis Direct complication of psoriasis (DC 7816). Must be rated separately under the appropriate musculoskeletal diagnostic code per the Note in 38 CFR 4.118. Report joint pain, swelling, and stiffness at your dermatology C&P exam and file a separate claim.
- Eczema / Atopic Dermatitis Frequently co claimed with or diagnosed alongside papulosquamous disorders. Rated under the General Rating Formula for the Skin. May be coded under DC 7806 (dermatitis or eczema) and evaluated on the same DBQ.
- Infectious Skin Conditions Secondary bacterial, fungal, or viral skin infections are common complications of chronic inflammatory skin conditions. Rated under DC 7820 and evaluated under the General Rating Formula for the Skin. File separately or as a secondary condition.
- Alopecia / Scarring Alopecia Hair loss can occur as a complication or co condition with skin diseases including discoid lupus, lichen planopilaris, and severe inflammatory disorders. Captured separately on the DBQ under alopecia fields.
- Depression / Anxiety Secondary to Skin Disease Chronic, visible skin conditions such as psoriasis and acne are strongly associated with depression, anxiety, and social isolation. A psychiatric condition secondary to a service connected skin disease may be separately ratable under 38 CFR 3.310.
- Hyperhidrosis Abnormal sweating can co occur with or be caused by skin conditions. Captured on the DBQ as a separate finding under DC 7830 and may be separately ratable.
- Vitiligo Loss of skin pigmentation rated under DC 7831 and captured separately on the DBQ. Can co occur with autoimmune skin conditions.
- Chronic Urticaria (Hives) Rated under DC 7825 and evaluated under the General Rating Formula for the Skin. Captured separately on the DBQ. May co occur with or be confused with other skin conditions.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.